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Abstract
Background: Acute renal failure is one of the most serious complications of envenoming resulting from Crotalus durissus
terrificus bites. This study evaluated the relevance of hyperuricemia and oxidative stress and the effects of allopurinol and
probenecid in renal dysfunction caused by direct nephrotoxicity of C. d. terrificus venom.
Methodology/Principal Findings: Hematocrit, protein, renal function and redox status were assessed in mice. High ratio of
oxidized/reduced glutathione and hyperuricemia induced by C. d. terrificus venom were ameliorated by both, allopurinol or
probenecid, but only allopurinol significantly reduced the lethality caused by C. d. terrificus venom. The effectiveness of
probenecid is compromised probably because it promoted hypercreatinemia and hypocreatinuria and worsed the urinary
hypo-osmolality in envenomed mice. In turn, the highest effectiveness of allopurinol might be due to its ability to diminish
the intracellular formation of uric acid.
Conclusions/Significance: Data provide consistent evidences linking uric acid with the acute renal failure induced by C. d.
terrificus venom, as well as that this envenoming in mice constitutes an attractive animal model suitable for studying the
hyperuricemia and that the allopurinol deserves to be clinically evaluated as an approach complementary to anti-snake
venom serotherapy.
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Introduction
Envenoming resulting from snake bite is recognized nowadays as
one of the major neglected public health issue within poor
communitiesliving intheruralareas ofseveralcountriesthroughout
the world. Because of serious misreporting, the true worldwide
burden of snake bite is not known, but according to conservative
countryestimatesusedtocalculatetheregionalestimates,Brazilhad
a fourth estimated numberof envenomings annually (30,000) [1]. In
Brazil, bites by snakes of genus Crotalus were responsible for 7.7% of
these, but accidents involving this genus originate the highest
mortality (about 2%) among registered snake bites [2]. Among the
species of this genus, Crotalus durissus terrificus is the most frequently
implicated in these accidents [3]. Because it is well vascularized, the
kidney is a particularly vulnerable organ to venom toxicity [4]. In
fact, the most serious complication of Crotalus snake bite is acute
renal failure (ARF) [5]. The prospective survey of 100 cases of
Crotalus bites followed from hospitalization to death or discharge in
Sa ˜o Paulo, Brazil, revealed a high prevalence of ARF (29%) in the
first 72 hours after the bite with the case fatality ratio of 10% [5].
Two primary events of the direct nephrotoxic effect of the C. d.
terrificus venom (vCdt) in mice are the oxidative stress in renal tissue
and an incidence of 100% of hyperuricemia over an incidence of
60% of hypercreatinemia [6–7]. Although hyperuricemia has also
been observed in human accidents with C. d. terrificus [8] and
others species of snakes [9], this parameter has not received any
special attention as a relevant factor in the etiology of ARF, mainly
because according to the recommendation of AKIN (Acute
Kidney Injury Network) the prominent criteria to identify ARF
should be the detection of changes in absolute values of serum
creatinine, plasma urea and urinary volume [5,10–12]. However,
it is well known that in many situations ARF is associated with a
rise in plasma uric acid as a result of both increased generation
and decreased excretion [13]. A marked hyperuricemia, currently
defined as uricemia higher than the maximum value of normal
range [14–15], occurs with intrarenal urate crystal deposition
leading to ARF [16–17], but rats with uricemia near three times
higher than the minimum value of normal range (mild
hyperuricemia) [14–15], as that caused in mice by vCdt [6–7],
also develop systemic hypertension, interstitial renal disease,
afferent arteriolopathy, increased renin expression [18–19] and
glomerular hypertrophy [20]. Experimentally, raising uric acid in
rats can induce these dysfunctions via a crystal-independent
mechanism [21–25]. It has also been reported that mild
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and within the endothelial [21] and vascular smooth muscle cells
[26], as well as in adipocytes [27]. However, paradoxically the uric
acid has been considered as circulating antioxidant which potently
reacts with superoxide anion, peroxynitrite, chelates iron-based
radicals [28] and prevents the oxidative inactivation of extracellular
superoxide dismutase [29]. High plasma levels [30] or the infusion
of uric acid [31] increased plasma antioxidant activity in humans.
Regarding the controversy about the effects of uric acid on
redox status, the involvement of uric acid and oxidative stress in
ARF induced by vCdt is an attractive reason to investigate this
envenomation. Moreover, clinical investigations have established
that antivenoms are highly effective in the neutralisation of toxins
responsible for systemic effects, but among the fatal cases of
Crotalus bites in Brazil 5% are patients treated with antivenom
[32]. Therefore, to know more about the role of uric acid in ARF
and to highlight potential complementary agents for the treatment
of envenoming by Crotalus snake bites, this study evaluated the
effects of uricostatic (allopurinol) and uricosuric (probenecid) drugs
on renal function (hematocrit, protein, osmolality, creatinine, uric
acid and urea) and oxidative stress (oxidized [GSSG] over reduced
[GSH] glutathione index and content of malondialdehyde
[MDA]) in mice inoculated with vCdt.
Methods
Ethics statement
The conducts and procedures involving animal experiments
were approved by the Butantan Institute Committee for Ethics in
Animal Experiments (License number CEUAIB 717/2010) in
compliance with the recommendations of the National Council for
the Control of Animal Experimentation of Brazil (CONCEA).
Preparation of venom solution
1.0 mg of lyophilized venom (provided by the Instituto
Butantan) was suspended in 1.0 mL of sterile phosphate buffered
saline (PBS) (Na2HPO4.7H2O, 19.3 g/L; NaH2PO4.H2O, 3.9 g/
L; NaCl, 8.77 g/L; pH 7.4), under mild mixing, for 10 min, at
4uC and, then, centrifuged at 10,1926g for 20 min at 4uC. The
pellet was discarded and the supernatant was aliquoted and stored
at 220uC at a maximum time of one week and administered
intraperitoneally (ip) at a dose of 1.024 mg venom/20 g body mass
(80%LD50) in a maximum volume of 0.2 mL [6–7]. The same lot
of venom was used throughout this study.
Preparation of allopurinol
Allopurinol (4-Hydroxypyrazolo[3,4-d]pyrimidine) (Sigma,
USA) was dissolved in 1 M NaOH at a concentration of
50 mg/mL and subsequently diluted (1:5) in PBS just before
administration by gavage per oral (po) at a dose of 2 mg/20 g body
mass in a maximum volume of 0.2 mL.
Preparation of probenecid
Probenecid (p-[Dipropylsulfamoyl]benzoic acid) (Sigma, USA)
was dissolved in 1 M NaOH at a concentration of 600 mg/mL and
subsequently diluted (1:5) in PBS just before administration po at a
dose of 24 mg/20 g body mass in a maximum volume of 0.2 mL.
Animals, treatments and urine collection
Adult male Swiss mice, weighing 18–20 g, provided by the
Animal Facility of the Instituto Butantan, were maintained in
polyethylene cages (inside length6width6height=56635619 cm)
with food and water ad libitum, in a container with controlled
temperature of 25uC, relative humidity of 65.360.9% and
12 h :12 h photoperiod light: dark (lights on at 6:00 am).
Animals were divided into eight groups, which received: (i)
0.2 mL PBS, ip (control ip); (ii) 0.2 mL PBS, po (control po); (iii)
0.2 mL PBS, ip and after 2 h, 0.2 mL PBS, po (control ip+po); (iv)
2 mg allopurinol in 0.2 mL PBS per 20 g body mass, po (NL); (v)
24 mg probenecid in 0.2 mL PBS per 20 g body mass, po (PB); (vi)
1.024 mg venom in 0.2 mL PBS per 20 g body mass, ip
(80%LD50) (vCdt); (vii) 80%LD50 vCdt, ip and after 2 h, 2 mg
allopurinol in 0.2 mL PBS per 20 g body mass, po (vCdt+NL); (viii)
80%LD50 vCdt, ip and after 2 h, 24 mg probenecid in 0.2 mL
PBS per 20 g body mass, po (vCdt+PB). Immediately after
treatments, each group was placed in appropriate metabolic cages
for urine collection, which was performed 24 h after venom
injection. Pooled urine was centrifuged at 2,5646g, for 5 min, at
4uC; the supernatant was stored at 280uC, for the appropriate
procedures. Immediately after urine collection, animals were
anesthetized for blood and kidneys collection.
Lethality
It was monitored at intervals of one hour for 24 h, starting after
administration of venom or vehicle or drugs alone.
Obtaining kidneys and plasma, and measurement of
hematocrit
The animals were anesthetized with xylazin (Calmiun, Agener
Unia ˜o, Brazil) 0.1% and ketamine (Cetamin, Syntec, Brazil) 1% (ip,
0.1 mL/10 g body mass). Then, the blood was collected with
heparinized Pasteur pipette after scission in right axillary plexus.
The thoracic cavity was opened to perform cardiac perfusion with
50 mM PBS, over a periodof5 min at a flowrateof 8–10 mL/min.
Immediately after perfusion, kidneys were removed, frozen in dry
iceand storedfora maximumperiodof10days,at280uC,until the
use in the appropriate procedures. Measurement of hematocrit was
made in duplicate of individual samples, in micro-hematocrit
capillary tubes, centrifuged at 3,000 rpm for 5 min, at room
temperature (centrifuge HT model H240). For plasma obtainment,
blood was centrifuged individually at 5,2326g for 5 min, at 4uC.
Author Summary
In Brazil, among registered snake bites, those by the genus
Crotalus originate the highest mortality rate. The rattle-
snake Crotalus durissus terrificus is the most frequently
implicated in these accidents. The kidney is a particularly
vulnerable organ to the venom of this rattlesnake. In fact,
the most serious complication of Crotalus snake bite is the
renal dysfunction, and among the fatal cases of Crotalus
bites in Brazil 5% are patients treated with antivenom. The
hyperuricemia has been observed in human accidents with
snake venoms, but this parameter has not received any
special attention as a relevant factor in the etiology of
renal dysfunction caused by these venoms. This study
examined the effects of treatments with low-cost and low-
risk uricostatic (allopurinol) and uricosuric (probenecid)
drugs on the envenomation by C. d. terrificus, showing that
allopurinol and probenecid mitigated certain nephrotoxic
effects, as well as the survival of envenomed mice was
improved through the effects of allopurinol on reduction
of oxidative stress and intracellular formation of uric acid.
This new knowledge provides consistent evidences linking
uric acid with the renal dysfunction induced by rattlesnake
bites and that the allopurinol deserves to be clinically
evaluated as an approach complementary to anti-snake
venom serotherapy.
Snake Venom, Hyperuricemia and Oxidative Stress
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Total protein was measured, photometrically (Bio-Tek Power
Wave XR spectrophotometer), at 630 nm, in triplicates, in
samples of plasma (diluted 500-fold) and pool of urine (diluted
75-fold), by the method of Bradford [33], using a Bio-Rad protein
assay reagent (Hercules, USA). Protein contents were extrapolated
by comparison with standard curves of bovine serum albumin
(BSA) in the same diluent.
Osmolality, creatinine, uric acid and urea
The measurements were performed as described by Marinho
et al. [34]. Briefly, osmolality was determined in triplicates of
10 mL with a cryoscopic osmometer (Osmette II Fisher) and
creatinine, uric acid, and urea were photometrically quantified in
triplicate of individual plasma and pooled urine samples.
Oxidative stress
Oxidative stress was evaluated on renal cortex and medulla
from dissected kidneys stored at 280uC.
GSSG and GSH were fluorometrically measured as described
by Yamasaki et al. [6]. For this purpose, cortex and medulla were
homogenized in 0.1 M phosphate buffer, with 0.005 M EDTA,
pH 8.0 (PBEDTA) plus 5.26% HPO3 (0.1 g tissue/1.5 mL
PBEDTA plus 0.4 mL 25% HPO3), at 800 rpm for 3 min. These
homogenates were ultracentrifuged at 100,0006g for 30 min. The
pellet was discarded and the supernatant was immediately used.
All steps were carried out at 4uC.
MDA was assayed based on the method described by
Selmanoglu et al. [35]. The reaction solution was prepared with
90 mL of 8.1% SDS; 675 mL of 20% acetic acid solution (pH 3.5
adjusted with NaOH); and 675 mL of 0.8% aqueous solution of
thiobarbituric acid. 90 mL of tissue homogenates (10% [0.1 g/mL]
prepared in 1.15% KCl) was added to this solution and then the
volume was made up to 1.8 mL with distilled water. This mixture
was kept in a 98uC dry bath for about 1 h and subsequently
centrifuged at 2,5006g for 10 min at 4uC. The supernatant was
measured at 532 nm. The 1,1,3,3-tetraethoxypropane was used as
a standard for MDA.
Histology
The kidneys were fixed in 4% paraformaldehyde solution in
0.1 M NAOH and 0.1 M sodium tetraborate, processed in the
routine histological processes, 10-mm-thick sagittal sections were
prepared and stained with hematoxylin and eosin for light
microscopy examination.
Statistical analysis
Data are shown as mean 6 standard error of the mean (SEM)
and were analyzed using GraphPad Prism
TM software packages.
Regression analyses were performed to obtain standard curves of
protein, 1,1,3,3-tetraethoxypropane, GSH and GSSG. One-way
analysis of variance (ANOVA) followed, when differences were
detected, by the Newman-Keuls test was performed to compare
values among groups. Lethality data were analyzed by the two-
sided Fisher’s exact test. In all the calculations, a minimum critical
level of p,0.05 was set.
Results
Standardization of controls
Considering that various checked controls (ip, po and ip+po)
presented statistically similar values for mortality, creatinine, uric
acid and urea, the group that received vehicle (PBS) by ip and po
routes (group ip+po), both routes of administration of venom and
drugs, was adopted as control.
Lethality
Table 1 shows that the lethality of 80%LD50 of vCdt (43%) at
24 h was about the theoretically expected (40%) and did not differ
statistically from that of the vCdt group treated with probenecid
(25%). The lethality rate at 24 h was null in all control groups and
in those treated with allopurinol or probenecid alone, as well as
significantly reduced about 58% (from 43% to 18%) in vCdt group
treated with allopurinol. Most deaths occurred between 14–16 h
and fewer between 16–18 h in envenomed mice. In envenomed
mice treated with probenecid most deaths occurred between 16–
18 h while in envenomed mice treated with allopurinol occurred
between 18–20 h.
Renal function parameters
Figure 1 shows that hematocrit and plasma osmolality did not
differ among all examined groups. Allopurinol or vCdt alone, or the
association of vCdt with probenecid caused hypercreatinemia, in
comparison with control (ip+po), but envenomed animals treated
with allopurinol had a mitigation of this hypercreatinemia. The
rise of uricemia induced by vCdt was normalized by allopurinol
and probenecid. Compared with control, allopurinol alone caused
hypouremia. Allopurinol associated with vCdt caused hyperpro-
teinemia.
Figure 2 shows that urinary urea was not affected by the
treatments under study. Relative to control, urinary osmolality and
urinary content of uric acid were diminished by vCdt. Allopurinol
and probenecid alone caused a rise in urinary osmolality, but only
the treatment of envenomed animals with allopurinol restored this
parameter to a level of control group. Urinary content of uric acid
in envenomed animals was normalized only by treatment with
probenecid. The association of probenecid and vCdt caused
hypocreatinuria. Allopurinol alone caused hyperproteinuria.
Oxidative stress
Figure 3 shows that the pattern of changes on GSH, GSSG and
GSSG/GSH ratio caused by all the treatments under study was
similar between the renal cortex and medulla, in comparison with
Table 1. Assessment of lethality after treatments.
Treatments
Number
of mice Time course (h) of lethality rate (%)
0–14 14–16 16–18 18–20 20–23 23–24
control ip 5 0 00000
control po 6 0 00000
control ip+po 5 0 00000
NL po 9 0 00000
PB po 1 00 00000
vCdt ip 2 80 2 9 1 4 004 3 *
vCdt ip+NL po 40 0 0 3 15 0 18
vCdt ip+PB po 36 0 3 16 6 0 25*
Mice treated intraperitoneally (ip) and/or per oral (po) with vehicle (control),
allopurinol (NL), probenecid (PB) and Crotalus durissus terrificus venom (vCdt)
followed by NL (vCdt+NL) or PB (vCdt+PB) after 2 h.
*Lethality at 24 h only differed in vCdt+PB (p=0.0432) and vCdt (p=0.0016)
compared with all other groups. Lethality at 24 h did not differ between
vCdt+PB and vCdt (p=0.1811) (Two-sided Fisher’s exact test).
doi:10.1371/journal.pntd.0001312.t001
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study. GSSG and GSSG/GSH ratio were increased by vCdt.
Probenecid diminished GSSG/GSH ratio in non-envenomed and
both allopurinol and probenecid normalized GSSG and GSSG/
GSH ratio in envenomed mice. Probenecid and vCdt did not affect
MDA in the renal cortex but slightly diminished MDA in the renal
Figure 1. Effects of treatments on hematocrit and renal function parameters in the blood plasma. Mice treated with vehicle (control),
allopurinol (NL), probenecid (PB) and Crotalus durissus terrificus venom (vCdt) followed by NL (vCdt+NL) or PB (vCdt+PB) after 2 h. Values are means 6
SEM. Number of animals in parentheses. Comparison of the same parameter among groups: ANOVA (Hematocrit, p=0.1807; Osmolality, p=0.3577;
Creatinine, p,0.006; Uric acid, p,0.0001; Urea, p,0.003; Protein, p,0.0001). Post hoc Student-Newman-Keuls (different letters over the bars indicate
statistical differences: creatinine and urea, p,0.05; uric acid and protein, p,0.01).
doi:10.1371/journal.pntd.0001312.g001
Figure 2. Effects of treatments on renal function parameters in the urine. Mice treated with vehicle (control), allopurinol (NL), probenecid
(PB) and Crotalus durissus terrificus venom (vCdt) followed by NL (vCdt+NL) or PB (vCdt+PB) after 2 h. Values are means 6 SEM of pooled animals, 16
(control), 9 (NL), 10 (PB), 12 (vCdt), 22 (vCdt+NL) and 12 (vCdt+PB) in triplicates. Comparison of the same parameter among groups: ANOVA
(Osmolality, p,0.0001; Creatinine, p,0.0009; Uric acid, p,0.005; Urea, p=0.06; Protein, p,0.001). Post hoc Student-Newman-Keuls (different letters
over the bars indicate statistical differences: osmolality and creatinine, p,0.01; uric acid and protein, p,0.05).
doi:10.1371/journal.pntd.0001312.g002
Snake Venom, Hyperuricemia and Oxidative Stress
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medulla in envenomed and markedly in normal healthy mice.
Histology
Histopathological changes such as edema, fibrosis and tubular
necrosis were observed in envenomed mice, corroborating
previous findings about direct nephrotoxic effects of this venom
[5,32,36]. These changes were predominant in the cortex. The
kidneys of animals treated with allopurinol or probenecid have
much less intense and less numerous alterations, with an
appearance that resembles that of the control animals. Some of
these histological aspects were illustrated in Figure 4.
Discussion
ARF induced by vCdt through direct renal action in mice
promotes histological changes, hyperuricemia, hypercreatinemia,
increased renal GSSG/GSH ratio with unaltered lipidic peroxi-
dation, hypo-osmolality, decreased excretion of uric acid in urine
and death after a time course higher than 14 h. Epidemiological
data compiling reports of snakebites in Brazil during 100 years
show that the average time elapsed between snakebites in humans
and the medical attendance is generally less than 6 hours [37]. In
the case of envenomation by rattlesnake, urinary changes do not
usually occur before the 12th hour [2] and the available data on
the distribution of the number of attendances, according to the
average time elapsed between the accident and the attendance is
about 67% (,3 h), 14% (3–6 h), 11% (.6 h), 8% (unknown) [38].
In the present study allopurinol and probenecid administered 2 h
after vCdt fully restore uricemia and renal GSSG/GSH ratio and
ameliorate histopathological changes caused by this venom.
Additionally, probenecid restores uricosuria, while allopurinol
restores the normal levels of urinary osmolality in envenomed
mice. Above all, allopurinol significantly decreases the lethality of
vCdt. This is the first study correlating agents capable of reducing
renal uric acid with the ARF induced by animal venoms.
A typical property of allopurinol is to decrease the concentration
of uric acid and urates relatively insoluble in tissues, plasma and
urine. Allopurinol blocks the formation of uric acid, reducing its
synthesis by competitive inhibition of xanthine oxidase [39].
Allopurinol is rapidly and extensively metabolised to oxypurinol,
and its hypouricemic efficacy is due very largely to this metabolite
[39]. Thus, its beneficial effect on envenomation by vCdt should be
associated to the cell lysis caused by this venom, which contributes
Figure 3. Effects of treatments on renal oxidative stress. Reduced glutathione (GSH), oxidized glutathione (GSSG) and malondialdehyde
(MDA) were measured in renal cortex and medulla from mice treated with vehicle (control), allopurinol (NL), probenecid (PB) and Crotalus durissus
terrificus venom (vCdt) followed by NL (vCdt+NL) or PB (vCdt+PB) after 2 h. Values are means 6 SEM. Number of animals in parentheses. Comparison
of the same parameter among groups: ANOVA (cortex: GSH, p=0.6489; GSSG, p,0.0004; GSSG/GSH, p,0.0001; MDA, p,0.0001; medulla: GSH,
p=0.8440; GSSG, p,0.0001; GSSG/GSH, p,0.0009; MDA, p,0.0001). Post hoc Student-Newman-Keuls (different letters over the bars indicate
statistical differences: p,0.05).
doi:10.1371/journal.pntd.0001312.g003
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the other hand, probenecid is an inducer of uric acid excretion in
urine, without influence on its formation [40], acting as an
inhibitor of an organic anion transport exchanger that blocks the
entry of uric acid into the cells [41–42]. Allopurinol is approved by
the US Food and Drug Administration for a dose up to 800 mg/
day and is available as a low-cost generic drug [43]. Allopurinol at
the same dose used in the present study and administered orally
for 7 days possess potent hypouricemic effect in mice [44].
Probenecid at the same dose and route used in the present study
accelerates the uric acid excretion in mice [45]. A single dose of
allopurinol by the same route and thirty times lower than that used
here is effective as uricostatic [46], while a fiftieth part of a single
dose of probenecid by the same route used in the present study
promotes a consistent uricosuric response in human subjects [47].
The same dose of allopurinol used here, but administered by intra-
arterial infusion, totally abolishes the vascular oxidative stress [40],
while about a half of this dose administered by the same route
improves peripheral vasodilator capacity and blood flow in
humans with chronic heart failure [48]. In the present study,
despite having played its excretory activity in envenomed mice,
probenecid did not provide the same beneficial effect of
allopurinol against the lethality (it tended to reduce mortality,
but without statistical significance). Furthermore, a rise of the
antioxidant uric acid in the plasma paradoxically induced
increased GSSG/GSH ratio and unaltered level of MDA in
kidneys of mice envenomed by vCdt; and allopurinol and
probenecid were both efficient in restoring this GSSG/GSH ratio
to normal value. Other studies have reported that simvastatin [6]
and lipoic acid [7] also ameliorated the GSSG/GSH ratio in the
renal tissue, but these drugs did not affect the lethality caused by
vCdt in mice. Thus, only the reduction of this index of oxidative
stress was not responsible for the reduction of the lethality of vCdt.
Furthermore, the antioxidant effect of simvastatin [6], lipoic acid
[7], allopurinol and probenecid, as well as the lethality of vCdt
could not be related simply to a uric acid-associated crystal-
dependent mechanism. Therefore, what are the additional
beneficial effects of allopurinol in this envenomation?
Allopurinol could be protective due to the blocking of xanthine
oxidase-associated oxidants [49] as opposed to the simple uric
acid-lowering effect of probenecid, since the pathway of xanthine
oxidase, which leads to the synthesis of uric acid, can form reactive
oxygen species such as MDA [35], which can attack a wide variety
of cellular components. In fact, the present study shows that
besides reducing the uric acid, allopurinol was active on MDA-
mediated lipid peroxidation in the kidney. However, we did not
observe any significant changes in lipid peroxidation expressed by
MDA level in envenomed mice as compared with healthy controls.
Allopurinol at a dose twice lower has reported to be more effective
than probenecid in improving endothelial function in patients with
congestive heart failure, despite equivalent lowering of uric acid
[40]; and in the present study the ratio between the doses of
allopurinol and probenecid was 1:12. It is known that uric acid
itself may cause endothelial dysfunction, which requires intracel-
lular uptake of uric acid (as noted by the ability of probenecid to
block the effects of uric acid on vascular cells) [21]. In this regard,
allopurinol may be more effective at lowering intracellular uric
acid levels when cellular production is high such as observed in
heart failure [40]. These findings suggest that increased cellular
production of uric acid is an important cause of the hyperuricemia
induced by vCdt. Furthermore, uric acid, while being an
antioxidant in the extracellular environment, has direct pro-
oxidative effects once it gains entry into cells [30]. When uric acid
reacts with oxidants such as peroxynitrite, it generates both
radicals and alkylating species as it degrades peroxynitrite [50]. In
the extracellular environment, these substances may dissipate into
the circulation, but these substances are highly likely to be reactive
with local constituents in the intracellular environment. In
Figure 4. Histopathological features of renal samples. Slides of hematoxilin-eosin stained sagittal sections from representative kidneys of mice
treated with: I and II: vehicle (control); see normal appearance of Bowman’s capsule (BC), glomerulus (G), macula densa (DM) and distal tubule (DT);
III, IV and V: C. d. terrificus venom; the most frequently changes detected were edema (*), fibrosis (1) with cell influx (2), and tubular necrosis with
tubules markedly dilated and cellular debris in the lumen (3, 4) and in the brush border (BB). Treatments of envenomed with allopurinol or
probenecid acted indistinguishably to ameliorate the frequency and the intensity of detectable histological changes comparatively with untreated
envenomed mice. Bars=100 mm.
doi:10.1371/journal.pntd.0001312.g004
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antioxidant in a hydrophilic environment (such as present in the
extracellular environment) as opposed to the primarily hydropho-
bic intracellular environment [51]. On the other hand, it is well
documented that probenecid reduces the uric acid excretion rate
at a low dose and accelerates it at a high dose, showing the so-
called paradoxical effect [45]. The differential determinants of the
low efficiency of probenecid compared to allopurinol against the
lethality of vCdt could be associated with this paradoxical effect
and/or with effects that occur only with the administration in
envenomed animals. In fact, this last kind of effect of allopurinol is
only the hyperproteinemia, while probenecid promotes hyper-
creatinemia, hypocreatinuria and aggravation of the urinary hypo-
osmolality in envenomed mice. Based on this framework of
evidences, the most likely mechanisms of differential action of
allopurinol and probenecid on the lethality induced by vCdt are
sketched in Figure 5.
In conclusion, the evidences presented here support the
hypothesis proposed by Yamasaki et al. [6] that the hyperuricemia
is involved in the early stages of ARF induced by direct nephrotoxic
action of vCdt. Data shows that this envenoming constitutes an
attractive animal model suitable for studying the hyperuricemia and
that the therapeutic intervention with allopurinol at an early stage
can prevent or recover its renal effects and especially prevent its
lethality in mice. While one must be cautious in extrapolating
animal models to human disease, this study provides a consistent
evidence linking uric acid with the ARF induced by vCdt and should
stimulate clinical trials to address whether allopurinol may
contribute to anti-snake venom serotherapy.
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Figure 5. Schematic diagram depicting mechanisms and hypothetical actions of allopurinol and probenecid in vCdt nephrotoxicity.
ARF induced by vCdt occurs through indirect and direct actions leading to lethality. Direct actions of vCdt generate hyperuricemia and renal oxidative
stress. Uric acid has direct intracellular pro-oxidative effects. Allopurinol and probenecid restore uricemia and renal oxidative stress caused by vCdt.
These beneficial effects must be, in part, exerted through a reduction of intracellular deposit of urate, as a consequence of the reduction of uric acid
formation due to the inhibition of xanthine oxidase (allopurinol) or an inhibition of an organic anion transport exchanger that blocks the entry of uric
acid into the cells (probenecid). Allopurinol, but not probenecid, protects against the lethality caused by vCdt. This differential protective effect of
allopurinol is not related to the blocking of xanthine oxidase-associated oxidants, but it is likely related to the blocking of oxidant effects of increased
production of uric acid in the intracellular environment more than the entry of uric acid into the cells.
doi:10.1371/journal.pntd.0001312.g005
Snake Venom, Hyperuricemia and Oxidative Stress
www.plosntds.org 7 September 2011 | Volume 5 | Issue 9 | e1312References
1. KasturiratneA,Rajitha-WickremasingheA,deSilvaN,Kithsiri-GunawardenaN,
Pathmeswaran A, et al. (2008) The Global Burden of Snakebite: A Literature
Analysis and Modelling Based on Regional Estimates of Envenoming and Deaths.
PLoS Medicine 5: 218.
2. Brazilian Ministry of Health (2001) Manual de Diagnostico e Tratamento de
Acidentes por Animais Peconhentos. 2nd edition. Brası ´lia, Brazil: Fundacao
Nacional de Saude.
3. Luzia S, Cruz LS, Vargas R, Lopes AA (2009) Snakebite envenomation and
death in the developing world. Ethnicity & Disease 19[Suppl1]: S142–S146.
4. Sitprija V (2006) Snakebite nephropathy. Nephrology 11: 442–448.
5. Pinho FM, Zanneta DM, Burdmann EA (2005) Acute renal failure after Crotalus
durissus snakebite: a prospective survey on 100 patients. Kidney Int 67: 659–667.
6. Yamasaki SC, Villarroel JS, Barone JM, Alegre VS, Zambotti-Villela L, et al.
(2008) Crotalus durissus terrificus venom and simvastatin affect oxidative stress and
plasma, urine and renal aminopeptidases in mice. Toxicon 52: 445–454.
7. Alegre VS, Barone JM, Yamasaki SC, Zambotti-Villela L, Silveira PF (2010)
Lipoic acid effects on renal function, aminopeptidase activities and oxidative
stress in Crotalus durissus terrificus envenomation in mice. Toxicon 56: 402–410.
8. Magalhaes RA, Ribeiro MMF, Rezende NA, Amaral CFS (1986) Rabdomio ´lise
secunda ´ria a acidente ofı ´dico crota ´lico (Crotalus durissus terrificus). Rev Inst Med
trop Sao Paulo 28: 228–233.
9. Kanjanabuch T, Sitprija V (2008) Snakebite nephrotoxicity in Asia Semin.
Nephrol 28: 363–372.
10. Cerda ´ J, Lameire N, Eggers P, Pannu N, Uchino S, et al. (2008) Epidemiology of
acute kidney injury. Clin J Am Soc Nephrol 3: 881–886.
11. Davenport A, Bouman C, Kirpalani A, Skippen P, Tolwani A, et al. (2008)
Delivery of renal replacement therapy in acute kidney injury: what are the key
issues? Clin J Am Soc Nephrol 3: 869–875.
12. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, et al. (2007) Acute
Kidney Injury Network. Acute Kidney Injury Network: report of an initiative to
improve outcomes in acute kidney injury. Crit Care 11: R31.
13. Ejaz AA, Mu W, Kang DH, Roncal C, Sautin YY, et al. (2007) Could uric acid
have a role in acute renal failure? Clin J Am Soc Nephrol 2: 16–21.
14. Feig DI, Kang D-H, Johnson RJ (2008) Uric Acid and Cardiovascular Risk.
N Engl J Med 359: 1811–1821.
15. Sanchez-Lozada LG, Soto V, Tapia E, Avila-Casado C, Sautin YY, et al. (2008)
Role of oxidative stress in the renal abnormalities induced by experimental
hyperuricemia. Am J Physiol Renal Physiol 295: F1134–F1141.
16. Stavric B, Johnson WJ, Grice HC (1969) Uric acid nephropathy: an
experimental model. Proc Soc Exp Biol Med 130: 512–516.
17. Bradley A, Caskey CT (1994) Hyperuricemia and urate nephropathy in urate
oxidase deficient mice. Proc Natl Acad Sci USA 91: 742–746.
18. Mazzali M, Kanellis J, Han L, Feng L, Chen Q, et al. (2002) Hyperuricemia
induces a primary renal arteriolopathy in rats by a blood pressure independent
mechanism. Am J Physiol Renal Physiol 6: F991–F997.
19. Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, et al. (2005)
Hyperuricemia induces endothelial dysfunction. Kidney Int 67: 1739–1742.
20. Nakagawa T, Mazzali M, Kang DH, Kanellis J, Watanabe S, et al. (2003)
Hyperuricemia causes glomerular hypertrophy in the rat. Am J Nephrol 23: 2–7.
21. Yu M-A, Sanches-Lozada L, Johnson RJ, Kang D-H (2010) Oxidative stress
with an activation of the renin–angiotensin system in human vascular
endothelial cells as a novel mechanism of uric acid-induced endothelial
dysfunction. J Hypertens 28: 1234–1242.
22. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, et al. (2001) Elevated
uric acid increases blood pressure in the rat by a novel crystalindependent
mechanism. Hypertension 38: 1101–1106.
23. Zharikov S, Krotova K, Hu H, Baylis C, Johnson RJ, et al. (2008) Uric acid
decreases NO production and increases arginase activity in cultured pulmonary
artery endothelial cells. Am J Physiol Cell Physiol 295: 1183–1190.
24. Kang DH, Park SK, Lee IK, Johnson RJ (2005) Uric acid-induced C-reactive
protein expression: implication on cell proliferation and nitric oxide production
of human vascular cells. J Am Soc Nephrol 16: 3553–3562.
25. Gersch C, Palii SP, Kim KM, Angerhofer A, Johnson RJ, et al. (2008)
Inactivation of nitric oxide by uric acid. Nucleosides Nucleotides Nucleic Acids
27: 967–978.
26. Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, et al. (2008) Uric
acid stimulates vascular smooth muscle cell proliferation and oxidative stress via
the vascular renin–angiotensin system. J Hypertens 26: 269–275.
27. Sautin YY, Nakagawa T, Zharikov S, Johnson RJ (2007) Adverse effects of the
classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/
nitrosative stress. Am J Physiol Cell Physiol 293: 584–596.
28. Becker BF (1993) Towards the physiological function of uric acid. Free Radic
Biol Med 14: 615–631.
29. Hink HU, Santanam N, Dikalov S, McCann L, Nguyen AD, et al. (2002)
Peroxidase properties of extracellular superoxide dismutase: role of uric acid in
modulating in vivo activity. Arterioscler Thromb Vasc Biol 22: 1402–1408.
30. Ames BN, Cathcart R, Schwiers E, Hochstein P (1981) Uric acid provides an
antioxidant defense in humans against oxidant- and radical-caused aging and
cancer: a hypothesis. Proc Natl Acad Sci USA 78: 6858–6862.
31. Waring WS, Webb DJ, Maxwell SR (2001) Systemic uric acid administration
increases serum antioxidant capacity in healthy volunteers. J Cardiovasc
Pharmacol 38: 365–371.
32. Pinho FM, Vidal EC, Burdmann EA (2000) Atualizac ¸o ˜es em insuficie ˆncia renal
aguda: insuficie ˆncia renal apo ´s acidente crota ´lico. J Bras Nefrol 22: 162–168.
33. Bradford MM (1976) A rapid and sensitive method for the quantitation of
microgram quantities of protein utilizing the principle of protein-dye binding.
Analytical biochemist 72: 248–254.
34. Marinho CE, Olivo RA, Zambotti-Villela L, Ribeiro-de-Andrade TN,
Fernandes CM, et al. (2006) Renal and macrophage aminopeptidase activities
in cyclosporin-treated mice. Int Immunopharmacol 6: 415–425.
35. Selmanoglu G, Karacaoglu E, Kilic ¸ A, Koc ¸kaya EA, Akay MT (2011) Toxicity
of food contaminant furan on liver and kidney of growing male rats. Environ
Toxicol; DOI 10.1002/tox.20673.
36. Pinho FM, Yu L, Burdmann EA (2008) Snakebite-induced acute kidney injury
in Latin America. Semin Nephrol 28: 354–362.
37. Bochner R, Struchiner CJ (2003) Epidemiologia dos acidentes ofı ´dicos nos
u ´ltimos 100 anos no Brasil: uma revisa ˜o. Cad Sau ´de Pu ´blica 19: 7–16.
38. Pinho FM, Oliveira ES, Faleiros F (2004) Acidente ofı ´dico no estado de Goia ´s.
Rev Assoc Med Bras 50: 93–96.
39. Day RO, Graham GG, Hicks M, McLachlan AJ, Stockerm SL, et al. (2007)
Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypur-
inol. Clin Pharmacokinet 46: 623–644.
40. George J, Carr E, Davies J, Belch JJF, Struthers A (2006) High-dose allopurinol
improves endothelial function by profoundly reducing vascular oxidative stress
and not by lowering uric acid. Circulation 114: 2508–2516.
41. Kang DH, Han L, Ouyang X, Kahn AM, Kanellis J, et al. (2005) Uric acid
causes vascular smooth muscle cell proliferation by entering cells via a functional
urate transporter. Am J Nephrol 25: 425–433.
42. Price KL, Sautin YY, Long DA, Zhang L, Miyazaki H, et al. (2006) Human
vascular smooth muscle cells express a urate transporter. J Am Soc Nephrol 17:
1791–1795.
43. Chao J, Terkeltaub R (2009) A critical reappraisal of allopurinol dosing, safety,
and efficacy for hyperuricemia in gout. Curr Rheumatol Rep 11: 135–140.
44. Kong LD, Yang C, Ge F, Wang HD, Guo YS (2004) A Chinese herbal medicine
Ermiao wan reduces serum uric acid level and inhibits liver xanthine
dehydrogenase and xanthine oxidase in mice. J Ethnopharmacol 93: 325–330.
45. Yamada H, Kotaki H, Furitsu H, Sawada Y, Iga T (1999) Mechanism of
uricosuric action of E3040, a drug used to treat inflammatory bowel disease II:
study using DBA/2N mice. Biopharm Drug Dispos 20: 271–276.
46. Turnheim K, Krivanek P, Oberbauer R (1999) Pharmacokinetics and
pharmacodynamics of allopurinol in elderly and young subjects. Br J Clin
Pharmacol 48: 501–509.
47. Ca ´ceres A, Giro ´n LM, Martı ´nez AM (1987) Diuretic activity of plants used for
the treatment of urinary ailments in Guatemala. J Ethnopharmacol 19: 233–245.
48. Doehner W, Schoene N, Rauchhaus M, Leyva-Leon F, Pavitt DV, et al. (2002)
Hyperuricemic patients with chronic heart failure results from 2 placebo-
controlled studies. Circulation 105: 2619–2624.
49. Rhoden E, Teloken C, Lucas M, Rhoden C, Mauri M, et al. (2000) Protective
effect of allopurinol in the renal ischemia–reperfusion in uninephrectomized rats.
Gen Pharmacol 35: 189–193.
50. Sautin YY, Johnson RJ (2008) Uric acid: the oxidant–antioxidant paradox.
Nucleosides Nucleotides Nucleic Acids 27: 608–619.
51. Santos CX, Anjos EI, Augusto O (1999) Uric acid oxidation by peroxynitrite:
multiple reactions, free radical formation, and amplification of lipid oxidation.
Arch Biochem Biophys 372: 285–294.
Snake Venom, Hyperuricemia and Oxidative Stress
www.plosntds.org 8 September 2011 | Volume 5 | Issue 9 | e1312